List of Excipients in Branded Drug HAILEY 1.5/30

Generic Drugs Containing HAILEY 1.5/30

Company	Ingredient	NDC	Excipient
Glenmark Pharmaceuticals Inc USA	norethindrone acetate and ethinyl estradiol	68462-504	ACACIA
Glenmark Pharmaceuticals Inc USA	norethindrone acetate and ethinyl estradiol	68462-504	D&C YELLOW NO. 10
Glenmark Pharmaceuticals Inc USA	norethindrone acetate and ethinyl estradiol	68462-504	FD&C BLUE NO. 1
Glenmark Pharmaceuticals Inc USA	norethindrone acetate and ethinyl estradiol	68462-504	FD&C YELLOW NO. 6
Glenmark Pharmaceuticals Inc USA	norethindrone acetate and ethinyl estradiol	68462-504	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in HAILEY 1.5/30?

# Of NDCs	Excipient
1	ACACIA
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	FD&C YELLOW NO. 6
1	LACTOSE MONOHYDRATE

Hailey 1.5/30 Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Hailey 1.5/30 is a generic combined oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 0.03 mg per tablet. Its commercial value is driven by reliable low-cost manufacturing, supply continuity, pharmacy substitution, and patient adherence rather than by active-ingredient patent protection. The core excipient platform is a conventional immediate-release tablet system using lactose, starch, microcrystalline cellulose, povidone, and magnesium stearate. The strongest opportunities are manufacturing-cost reduction, excipient-supply resilience, packaging differentiation, and lifecycle extensions such as extended-cycle or adherence-oriented presentations.

What is Hailey 1.5/30?

Hailey 1.5/30 is a prescription oral contraceptive tablet marketed by Mayne Pharma. Each active tablet contains:

Attribute	Product information
Active ingredient	Norethindrone acetate
Active-ingredient strength	1.5 mg
Estrogen component	Ethinyl estradiol
Estrogen strength	0.03 mg, or 30 mcg
Dosage form	Immediate-release oral tablet
Therapeutic category	Combined hormonal contraceptive
Regulatory pathway	Abbreviated New Drug Application generic product
Common pack structure	21 active tablets, depending on marketed presentation
Reference product class	Norethindrone acetate and ethinyl estradiol oral contraceptives

The FDA label identifies Hailey 1.5/30 as an oral contraceptive containing a progestin and estrogen combination. The product is pharmacologically comparable to other norethindrone acetate/ethinyl estradiol 1.5 mg/30 mcg tablets, including branded and generic products sold under different names.[1]

What excipients are used in Hailey 1.5/30?

The reported inactive ingredients are conventional oral-tablet excipients:

Excipient	Primary function	Commercial relevance
Lactose monohydrate	Diluent and tablet filler	Low cost, widely available, established oral safety record
Microcrystalline cellulose	Filler and compression aid	Supports tablet hardness and content uniformity
Pregelatinized corn starch	Binder and disintegrant	Supports mechanical strength and tablet breakup
Povidone	Binder	Improves granulation and tablet cohesion
Magnesium stearate	Lubricant	Reduces sticking and ejection force during compression

The excipient combination is consistent with a conventional wet- or dry-granulated immediate-release tablet. It does not indicate a modified-release delivery system, gastro-resistant coating, osmotic mechanism, or other high-value drug-delivery technology.[1]

Why does the excipient platform matter?

The active ingredients are present at low dose relative to the tablet mass. That makes blend uniformity, segregation control, and process capability important. Norethindrone acetate is present at 1.5 mg, while ethinyl estradiol is present at only 30 mcg. The estrogen component therefore creates a high-potency, low-dose content-uniformity requirement.

A suitable excipient system must:

• Maintain uniform distribution of ethinyl estradiol through blending and compression.
• Provide rapid and reproducible disintegration.
• Avoid excessive lubricant levels that could slow dissolution.
• Support tablet robustness during packaging, shipping, and dispensing.
• Preserve stability under normal temperature and humidity conditions.
• Meet applicable United States Pharmacopeia and National Formulary requirements.

The principal technical risk is not excipient novelty. It is process control around low-dose hormonal actives.

What excipient strategy is most appropriate for Hailey 1.5/30?

A cost-efficient strategy should preserve the established immediate-release profile while improving manufacturing resilience.

Use a conventional direct-compression or dry-granulation platform

Microcrystalline cellulose and pregelatinized starch can provide compressibility and disintegration without introducing a complex excipient system. Direct compression may reduce processing steps, solvent use, and drying costs. Dry granulation can improve flow and segregation control when the low-dose active blend does not perform adequately in direct compression.

The preferred process depends on:

• Active-particle size and density.
• Blend uniformity at commercial batch scale.
• Tablet-weight variability.
• Dissolution performance.
• Compression-force sensitivity.
• Equipment available at the manufacturing site.

A formulation change should be evaluated against comparative dissolution, assay, content uniformity, impurities, stability, and bioequivalence requirements. For an established generic product, an excipient change that improves manufacturability but alters dissolution can create regulatory and supply risk.

Protect against lactose and starch supply disruption

Lactose monohydrate and corn-derived starch are widely available, but both remain exposed to supplier qualification, regional production, transportation, and agricultural-market variability. A second-source strategy is commercially valuable.

Potential alternatives include:

• Mannitol or dibasic calcium phosphate as partial or complete diluents.
• Crospovidone or sodium starch glycolate as alternative disintegrants.
• Copovidone or hydroxypropyl cellulose as alternative binders.
• Alternative grades of microcrystalline cellulose.
• Vegetable-derived magnesium stearate from qualified suppliers.

The preferred approach is platform standardization across multiple oral contraceptive products. A manufacturer using one validated excipient architecture for Hailey 1.5/30, lower-strength norethindrone/ethinyl estradiol products, and ferrous-fumarate-containing variants could reduce development and qualification costs.

Control magnesium stearate exposure

Magnesium stearate is necessary for manufacturing performance but can impair wetting and dissolution when over-lubrication occurs. The control strategy should specify:

• Lubrication time.
• Lubricant concentration.
• Shear conditions.
• Order of addition.
• Blend endpoint.
• Dissolution acceptance criteria.

This is a process opportunity rather than a patent opportunity. Better lubrication control can reduce tablet sticking, compression failures, and dissolution variability.

What formulations are protected by Hailey 1.5/30?

Hailey 1.5/30 is an immediate-release tablet formulation. Public product information does not indicate protection for a novel delivery mechanism, sustained release, transdermal system, vaginal ring, implant, or other differentiated dosage form.[1]

The likely formulation characteristics are:

Formulation element	Assessment
Immediate-release tablet	Core commercial formulation
Conventional diluent system	Low technical differentiation
Conventional binder and disintegrant system	Limited standalone exclusivity value
Film-coating technology	Not a major disclosed differentiator
Modified release	Not indicated
Multiparticulate delivery	Not indicated
Taste-masking technology	Not commercially central
Device combination	None

Excipient combinations can be described in patent claims, but conventional combinations involving lactose, starch, povidone, microcrystalline cellulose, and magnesium stearate generally face substantial prior-art limitations. A commercially meaningful patent position would more likely arise from a novel stability solution, impurity-control method, low-dose blending process, or differentiated dosage form.

What patents protect Hailey 1.5/30?

Hailey 1.5/30 does not appear to depend on a current composition-of-matter patent for norethindrone acetate or ethinyl estradiol. Both active ingredients have long histories of generic use. The principal commercial protection is therefore regulatory approval, manufacturing capability, supplier access, and distribution rather than a new-molecule patent.

Does Hailey 1.5/30 have Orange Book protection?

The Orange Book primarily identifies approved drug products, reference listed drugs, patents submitted for listed products, and applicable exclusivity information. A generic product such as Hailey 1.5/30 generally does not have the same branded-product patent profile as an innovator product. Patent certifications are made in connection with an abbreviated application and the patents associated with the reference listed drug.[2]

The practical implications are:

• No meaningful active-ingredient patent barrier is expected.
• Formulation patents would matter only if listed or otherwise enforceable against the relevant generic product.
• Method-of-use patents are less likely to create a durable barrier for a standard contraceptive generic.
• Patent expiration is not the primary determinant of Hailey 1.5/30 competition.
• FDA approval, manufacturing compliance, and commercial contracting are more important than patent term.

A definitive patent-number and expiration-date schedule cannot be derived from the product label alone. Public FDA resources should be used to confirm current Orange Book listings and application-specific certifications.[2,3]

When does Hailey 1.5/30 lose exclusivity?

Hailey 1.5/30 is already positioned as a generic product, so its principal exclusivity loss occurred before or at generic-market entry. It does not have a commercially important new chemical entity exclusivity period.

The relevant timeline is:

Event	Commercial effect
Original approval of norethindrone acetate/ethinyl estradiol products	Established the reference product class
Generic ANDA approval	Enabled multisource competition
Additional generic approvals	Increased substitution and price pressure
Formulary and wholesaler contracting	Became more important than patent exclusivity
Supply interruptions	Can temporarily improve realized pricing and market share
New lifecycle formulation	Could create differentiated commercial positioning

For a generic oral contraceptive, the absence of a patent barrier does not guarantee immediate competitor entry. ANDA development, bioequivalence, manufacturing validation, FDA inspection, product launch economics, and retailer or payer access all influence entry timing.

What generic entry risks exist for Hailey 1.5/30?

Generic-entry risk is high because the product has:

• Long-established active ingredients.
• A conventional oral-tablet dosage form.
• No apparent device dependency.
• No biologic manufacturing complexity.
• Broad historical use of the active-ingredient combination.
• Multiple potential suppliers of standard excipients.

Potential entrants can develop an equivalent tablet using a different excipient system, provided the product satisfies FDA requirements for pharmaceutical equivalence and bioequivalence.

What could delay generic entry?

Manufacturing and regulatory barriers remain relevant:

1. Low-dose ethinyl estradiol content uniformity.
2. Demonstration of comparable dissolution.
3. Control of hormonal impurities and degradation products.
4. Stability through the proposed shelf life.
5. Qualification of API and excipient suppliers.
6. FDA inspection readiness.
7. Commercial scale-up without blend segregation.
8. Market access and margin sufficient to justify launch.

These are execution barriers, not durable exclusion rights.

Which companies are challenging the Hailey 1.5/30 market?

The competitive set includes manufacturers of norethindrone acetate and ethinyl estradiol tablets at the same or similar strengths, as well as branded and generic alternatives such as:

• Mayne Pharma, through Hailey products.
• Generic oral-contraceptive manufacturers supplying pharmacies and wholesalers.
• Manufacturers of norethindrone/ethinyl estradiol products under other labels.
• Suppliers of related products containing ferrous fumarate placebo tablets.
• Branded or authorized-generic providers competing on adherence packaging and channel access.

Competition is usually based on acquisition cost, supply reliability, wholesaler service levels, payer coverage, pharmacy substitution, and product availability. A conventional excipient platform rarely supports a sustainable premium.

What commercial opportunities exist for excipients?

Supply-chain qualification

The most immediate opportunity is dual sourcing. Excipient manufacturers can compete for qualified supply of:

• Direct-compression lactose.
• Low-moisture microcrystalline cellulose.
• Pregelatinized starch.
• Povidone with controlled molecular-weight distribution.
• Low-peroxide or low-impurity grades.
• Vegetable-derived magnesium stearate.

A supplier that supports regulatory documentation, change-control management, and consistent lot-to-lot performance can gain share even without a novel excipient.

Low-dose blending technology

A manufacturer could differentiate through a premix or co-processed excipient system designed for low-dose hormones. The value proposition would be improved:

• Content uniformity.
• Blend homogeneity.
• Reduced segregation.
• Lower compression variability.
• Faster scale-up.
• More consistent dissolution.

Any premix strategy would need to preserve the approved product’s critical quality attributes and fit within FDA post-approval change requirements.

Patient-adherence packaging

Packaging is a stronger commercial opportunity than formulation novelty. Potential improvements include:

• Calendarized blister packs.
• High-contrast tablet-day labeling.
• Child-resistant wallet packs.
• Unit-dose packaging for pharmacy and mail-order channels.
• Packaging optimized for humidity protection.
• Packaging compatible with digital adherence programs.

These approaches can improve usability without changing the drug product’s pharmacology. They may also create branding or trade-dress value, although packaging protection is separate from pharmaceutical patent protection.

Extended-cycle and regimen innovation

An extended-cycle presentation could reduce withdrawal bleeding frequency and create a differentiated product. A commercial program might combine active tablets with a redesigned placebo interval or a different pack configuration. The opportunity would be regulatory and clinical, not simply excipient-driven.

A new regimen could require additional clinical, labeling, and bioequivalence work. It would also face competition from established extended-cycle contraceptives.

How does Hailey 1.5/30 compare with Hailey Fe?

Attribute	Hailey 1.5/30	Hailey Fe
Progestin	Norethindrone acetate 1.5 mg	Norethindrone acetate, strength depends on product
Estrogen	Ethinyl estradiol 30 mcg	Ethinyl estradiol, strength depends on product
Iron component	Not the defining feature	Ferrous fumarate in placebo tablets
Excipient complexity	Lower	Higher because of iron-containing tablets
Packaging opportunity	Calendarized active-tablet presentation	Stronger distinction between active and placebo tablets
Manufacturing risk	Low-dose hormone uniformity	Hormone uniformity plus iron-tablet control
Commercial positioning	Conventional generic contraception	Adherence-oriented product with iron-containing reminder tablets

Hailey Fe creates more opportunity for differentiated placebo-tablet color, labeling, tablet identity, and packaging. Hailey 1.5/30 has a simpler manufacturing profile and may be more attractive for cost-focused generic supply.

What FDA regulatory issues affect excipient changes?

FDA evaluates generic products against the reference listed drug through pharmaceutical-equivalence and bioequivalence standards. Excipient changes can trigger regulatory reporting, supplemental review, stability requirements, or new bioequivalence work depending on the nature and scale of the change.[2,4]

Key considerations include:

• Inactive Ingredient Database precedent.
• Excipient amount and route-of-administration history.
• Dissolution profile.
• Content uniformity.
• Assay and impurity profile.
• Tablet hardness and friability.
• Stability and packaging interaction.
• Labeling consistency.
• Manufacturing-site validation.

For a low-dose hormonal tablet, a formulation change that appears minor from a mass-balance perspective can be important if it changes blend behavior or drug release.

What is the patent strength of the Hailey 1.5/30 excipient estate?

The apparent patent strength is low for the conventional tablet formulation. A defensible competitive assessment is:

IP category	Strength
Active-ingredient composition of matter	Very low
Conventional excipient combination	Low
Immediate-release tablet process	Low to moderate, depending on claim specificity
Low-dose blending process	Moderate if supported by data and narrow claims
Stability or impurity-control technology	Moderate if technically differentiated
Packaging and adherence design	Moderate, but usually not a pharmaceutical patent moat
Method of contraception	Low for standard labeling
Manufacturing know-how	Moderate and commercially relevant
Supplier qualification and scale-up knowledge	Moderate, generally not public

The most valuable unpatented assets are likely process knowledge, validated supplier relationships, batch-history data, and reliable manufacturing performance.

What licensing deals and revenue exposure are relevant?

No major public licensing transaction is central to Hailey 1.5/30’s commercial identity. The product is marketed as a generic oral contraceptive rather than as a partnered innovative medicine. Revenue is therefore exposed to:

• Pharmacy benefit manager pricing.
• Generic substitution rates.
• Wholesaler inventory levels.
• Product shortages.
• Manufacturing-site concentration.
• Contract renewals.
• Competitor launches.
• Payer preference for equivalent products.

Product-specific revenue is generally not separately disclosed by public companies. The commercial opportunity is better assessed through prescription volume, market share, average selling price, gross-to-net deductions, and supply continuity than through patent duration.

What generic launch scenarios are most likely?

Low-price multisource launch

Several manufacturers compete on price, causing rapid erosion. This is the standard scenario for a mature immediate-release contraceptive.

Supply-constrained share gain

A manufacturer with reliable inventory gains share during competitor shortages. Excipient dual sourcing and redundant API supply are central to this strategy.

Premium generic packaging

A supplier differentiates through blister packaging, calendar labeling, mail-order compatibility, or adherence services. The price premium is likely limited but may improve channel access.

Lifecycle reformulation

A manufacturer develops an extended-cycle, simplified-regimen, or alternative dosage-form product. This requires a stronger regulatory program and may create greater commercial value than an excipient substitution.

What geographic markets are attractive?

The United States is attractive because of the size of the generic prescription market and established pharmacy-substitution channels. The principal barriers are FDA compliance, ANDA requirements, payer contracting, and intense price competition.

Other markets may offer opportunities through:

• Local regulatory pathways for established active ingredients.
• Government contraceptive procurement.
• Hospital and clinic tenders.
• Lower-cost regional manufacturing.
• Public-health distribution programs.
• Alternative pack sizes and labeling.

Excipients should be selected with global regulatory portability in mind. A formulation dependent on a highly regionalized excipient grade may increase variation in regulatory filings and supply planning.

Key Takeaways

• Hailey 1.5/30 is a conventional generic combined oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg.
• Its excipient system is based on lactose monohydrate, microcrystalline cellulose, pregelatinized corn starch, povidone, and magnesium stearate.
• The principal technical challenge is uniform distribution of the 30 mcg ethinyl estradiol dose.
• Active-ingredient patent protection is not the main commercial barrier.
• Conventional excipient patents are unlikely to create a strong moat.
• The best excipient opportunities are dual sourcing, co-processed low-dose blending systems, controlled lubrication, and robust moisture protection.
• Packaging and adherence design offer greater differentiation potential than a minor excipient substitution.
• Generic entry risk is high, while manufacturing compliance and supply reliability can temporarily protect market share.
• Product-specific revenue is not generally disclosed, so commercial assessment should focus on volume, pricing, substitution, supply continuity, and payer access.
• A genuinely differentiated extended-cycle or adherence-oriented product would require a broader regulatory and commercial program.

FAQs

Can lactose-free excipients be used in Hailey 1.5/30?

A lactose-free formulation is technically possible, but it would require development work to demonstrate equivalent content uniformity, dissolution, stability, and bioequivalence where required. Mannitol, microcrystalline cellulose, or dibasic calcium phosphate could be evaluated as alternatives.

Can Hailey 1.5/30 be converted into a chewable tablet?

A chewable product would be a new dosage-form strategy rather than a routine excipient change. Taste, dose uniformity, mechanical properties, patient acceptability, and labeling would require separate development and regulatory evaluation.

Does Hailey 1.5/30 have biosimilar competition?

No. Hailey 1.5/30 is a small-molecule oral tablet. The relevant competitive pathway is generic ANDA approval, not biosimilar approval under the Biologics Price Competition and Innovation Act.

Can a co-processed excipient create patent protection?

Potentially, but only if the co-processed system has novel and non-obvious composition or performance characteristics. A routine mixture of established tablet excipients is unlikely to provide strong enforceable protection.

Would a blister pack create regulatory exclusivity?

Packaging alone generally does not create drug exclusivity. It can support trade-dress, design, contractual, or adherence-based differentiation, but it does not replace a patent or FDA exclusivity period.

References

1. DailyMed. (n.d.). Hailey 1.5/30: Norethindrone acetate and ethinyl estradiol tablet prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.

4. U.S. Food and Drug Administration. (2014). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.